Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  News  >  Business Leaders  >  All news

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 
HomeAll newsMost read newsBusiness Leaders Biography 
Birthday : 08/11/1957
Place of birth : Tosu - Japan
Biography : Mr. Masayoshi Son is Chairman at Sprint Corp., Chairman at SoftBank Corp., Chairman at Yahoo Japan C
The feature you requested does not exist. However, we suggest the following feature:

Clinuvel Pharmaceuticals : confirms date of Annual General Meeting

10/06/2015 | 04:09am US/Eastern

In accordance with ASX listing rules 3.13.1 and 14.3, Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced it will hold its 2015 Annual General Meeting of shareholders on Tuesday November 24, 2015 at 10.00am AEST at Karstens Conference Centres, Level 09, 123 Queen Street, Melbourne, Victoria, Australia 3000.

A formal Notice of Meeting and the Company's Annual Report will be lodged with the ASX no later than October 23, 2015.

- End -

Media enquiries

Lachlan Hay, Clinuvel (UK) Ltd. +44 1372 860 765 Lachlan.Hay@clinuvel.com

Nick Miles, Cabinet Privé de Conseils s.a. +41 22 321 4540 miles@cpc-pr.com

Ted Agne, The Communications Strategy Group Inc. +1 718 631 3117 edagne@comstragroup.com

Investor enquiries


About Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe disorders. With its unique expertise in understanding the interaction of light and human skin, the company has identified patient populations with a clinical need for photoprotection and another population with a need for repigmentation. These patient groups range in size from 5,000 to 45 million. Clinuvel's lead compound, SCENESSE® (afamelanotide 16mg), a first-in-class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe, and has been approved by the European Commission for treating adults with EPP. Headquartered in Melbourne, Australia, Clinuvel has operations in Europe, the US and Singapore.

For more information go to http://www.clinuvel.com.

Forward-Looking Statements

This release to the Australian Securities Exchange and to press contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause Clinuvel's actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that the FDA may require additional studies beyond the studies planned for product candidates or may not provide regulatory clearances, including for SCENESSE®; that the FDA may not provide regulatory approval for any use of SCENESSE® or that the approval may be limited; that Clinuvel may never file an NDA for SCENESSE® regulatory approval in the US; that the Company may not be able to access adequate capital to move its vitiligo programs forward; that the Company may not be able to retain its current pharmaceutical and biotechnology key personnel and knowhow for further development of its product candidates or may not reach favourable agreements with potential pricing and reimbursement agencies in Europe and the US.

Level 5, 160 Queen Street T +61 3 9660 4900 www.clinuvel.com

Melbourne, Victoria 3000 F +61 3 9660 4999


distributed by
React to this article
Latest news about Masayoshi Son 
05/11 MASAYOSHI SON : Son says vice chairman Arora a strong future candidate to lead SoftBank
2014 MASAYOSHI SON : SoftBank Invests in Altaeros Energies'Buoyant Airborne Technology
2014 MASAYOSHI SON : Not just son, snapdeal co-founders too pitch in
2014 MASAYOSHI SON : Japan's SoftBank to invest $10 billion in India
2014 MASAYOSHI SON : Japan's SoftBank to invest USD 10 billion in India
2014 MASAYOSHI SON : SoftBank's first Sony smartphone deal takes aim at U.S. market
2014 MASAYOSHI SON : SoftBank's Son says new Sprint CEO a 'streetfighter', hints at price war
2014 MASAYOSHI SON : SoftBank to start selling personal robots next year
2013 MASAYOSHI SON : Third point has made no management proposals to SoftBank
2013 MASAYOSHI SON : SoftBank's Son buys Tokyo Tiffany building for $326 million -sources
2013 MASAYOSHI SON : Softbank CEO Son says 'very supportive' of Alibaba's partnership
2013 MASAYOSHI SON : Softbank on track to complete Sprint acquisition by July
2013 MASAYOSHI SON : SoftBank to meet Sprint investors, many eye higher bid
2013 MASAYOSHI SON : Ergen puts chips on Sprint in latest wireless bet
2012 MASAYOSHI SON : Raine Group arrives in big way as Softbank's adviser
1  2  3  4  5  6  7  8  9  10Next

Most Read News 
09/30DJCLAUDE DAUPHIN : Trafigura Founder Claude Dauphin Dies
09/30DJLLOYD BLANKFEIN : Is Goldman Sachs' Gary Cohn Ready to Step in for Lloyd Blankfein?
10/02DJWILLIAM MACAULAY : William Macaulay Bought 1.7 Million Shares
10/01 JACK DORSEY : Analysis - Square could take hit on IPO with Jack Dorsey leading Twitter
09/30 JACK DORSEY : As Twitter, Square interests converge, CEO Dorsey risks conflicts
09/30 MICHAEL O'LEARY : Ryanair has applied for slots at Paris Roissy and Orly airports - O'Leary
10/05 NELSON PELTZ : Nelson Peltz's Trian takes $2.5 billion stake in General Electric
More news

Popular Business Leaders 
William Ackman Jean-michel Aulas Liliane Bettencourt Vincent Bolloré Martin Bouygues Warren Buffett Jean-claude Decaux Michael Dell David Einhorn Albert Frère Bill Gates Guy Hands Carl Icahn Li Ka-shing Arnaud Lagardère Maurice Lévy Lakshmi Mittal Rupert Murdoch Larry Page John Paulson Nelson Peltz François-henri Pinault Ferdinand Piëch Wilbur Ross Howard Schultz Carlos Slim George Soros Ratan Tata Donald Trump Alain Weill
A-Z Business Leaders